Print

Oscient Pharmaceuticals Corporation (OSCI) Amends Factive Contract With LG Life Sciences, Ltd.; Licensing For Factive Drug Includes All Of European Union  
1/5/2007 11:15:41 AM

WALTHAM, Mass. (AP) -- Oscient Pharmaceuticals Corp. said Friday it amended a contract for its Factive antibiotic with LG Life Sciences Ltd. to include several European countries to the licensing agreement. The amendment means all nations within the European Union are now included and royalty rates reduced on future sales. The company said the move is aimed at enabling maximum investment in the antibiotic brand through a potential European partnership.

>>> Discuss This Story